An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex

NCT00000672 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

660

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]